Fast Track for Stem Cells: Detroit\u27s Hub for Research and Commercialization by Oprean, Amy
New Science
Volume 18 | Issue 1 Article 24
9-1-2010
Fast Track for Stem Cells: Detroit's Hub for
Research and Commercialization
Amy Oprean
Wayne State University
Follow this and additional works at: http://digitalcommons.wayne.edu/newscience
This Article is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in New Science by an
authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Oprean, Amy (2010) "Fast Track for Stem Cells: Detroit's Hub for Research and Commercialization," New Science: Vol. 18: Iss. 1,
Article 24.
Available at: http://digitalcommons.wayne.edu/newscience/vol18/iss1/24
Notes:
Fast track             for Stem Cells  
Detroit’s hub for research and                  commercialization
b y  A m y  O p r e a n
P
A
G
E
 5
4
✼
Since the U.S. ban on stem cell research was lifted on March 9, 2009, many pockets of promising 
research have sprung up across the country as 
scientists scramble to recharge their efforts in a field 
that holds tremendous potential.
Through a multitude of funding opportunities 
and exceptional expertise, Michigan’s University 
Research Corridor – the alliance between Wayne 
State University, University of Michigan and 
Michigan State University – has positioned the 
state to be a major hub for stem cell advancement. 
Detroit holds particular promise, housing 
both Wayne State University and Stem Cell 
Commercialization Center located at TechTown, the 
university’s research and technology park. Together, 
these entities are creating a gravitational pull for 
researchers and stem cell-based businesses around 
the world.
“We’ve set the stage not only for Detroit to be a 
place of important breakthroughs, but a place where 
breakthroughs will see a speedy crossover into the 
market and into people’s lives,” said Carol Brenner, 
associate professor of physiology in WSU’s School 
of Medicine. Brenner is one of Wayne State’s head 
stem cell researchers who is looking forward to 
advances this hub of innovation will make possible. 
“This is the place that I’ve wanted to see research 
my entire life,” Brenner said. “We are without 
a doubt still in the basic stages of research, but 
the possibility of what we can accomplish grows 
tremendously when there are this many minds in 
one place.”
Having worked in both fertility clinics and 
academia, Brenner’s 25 years of experience 
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with stem cells have the rare combination of 
embryology and basic research.  A diverse set of 
experts is also what brought her to Wayne State, 
where a multidisciplinary group of mitochondrial, 
embryonic and basic stem cell biology experts is 
one of the few of its kind in the country. The group, 
which is headed by Brenner and James Eliason, 
Ph.D., associate professor of internal medicine, is 
working to develop a new method for inducing 
pluripotency that may produce stem cells that  
are safe for therapeutics and can be used to  
model diseases. 
Improving technology
Brenner and the team are focusing on adult 
pluripotent stem cells, specialized cells that have 
been reprogrammed to take on many of the 
characteristics of embryonic stem cells. First formed 
in 2006 from mouse cells and in 2007 from human 
cells, pluripotent stem cells bypass ethical and legal 
issues related to embryonic stem cell research. The 
current industry standard for inducing pluripotency 
involves using lentiviruses. Although these stem 
cells can be very useful in modeling diseases, they 
would cause serious defects if put back into  
the body.
The group is working on a new method of 
inducing pluripotency invented by Jianjun Wang, 
Ph.D., associate professor of biochemistry in WSU’s 
School of Medicine. Gyula Acsadi, M.D., Ph.D., 
associate professor of pediatrics and Graham 
Parker, Ph.D., assistant professor of pediatrics in 
WSU’s School of Medicine, have joined Brenner 
and Wang in developing a method using “protein 
transduction” instead of viruses to induce 
pluripotency, with the goal of producing stem cells 
that can be put back into the body for therapeutics. 
“Once we successfully develop a method for 
producing therapeutic stem cells, the door is open 
for making precursors to specific organs, to making 
larger quantities of cells needed for therapies 
and even getting more use out of bone marrow,” 
Brenner said. 
With the expertise of Michael Shy, Ph.D., 
professor of neurology in Wayne State’s School 
of Medicine, the group is also using pluripotent 
stem cells to model neurodegenerative diseases. 
Their focus is on the role of mitochondria in the 
dysfunction of motor neurons, a phenomenon that 
occurs in nearly every neurodegenerative disease. 
“We suspect that many neurodegenerative diseases 
may share many common pathways that are related 
to the dysfunction of motor neurons,” Brenner said. 
“Previous studies at WSU suggest that mitochondria 
are somehow involved with this dysfunction.”
To start, the team is zeroing in on motor 
neuron dysfunction in patients with Charcot-
Marie Tooth disease, a nerve disorder characterized 
by loss of muscle tissue, and Spinal Muscular 
Atrophy, a neuromuscular disease characterized 
by degeneration of motor neurons. By inducing 
pluripotency in cells from people with these 
diseases, they will be able to observe the 
disease from its very beginning stages through 
development, allowing them to not only observe 
the role of mitochondria, but to identify biomarkers 
and develop a model for the disease. 
“Returning the cells back to an embryonic state 
allows us to go back to the early development and 
to try to understand the entire process of how the 
disease manifests,” Brenner said. “It’s like looking at 
an embryo with that disease.”
Getting a foot up on bringing the research into 
the next stage, Eliason has also started a company 
to commercialize the research. Mitostem, at 
TechTown, was formed to commercialize neural 
regeneration technology as it’s developed.
The commercialization center, which is headed 
by Eliason as executive director, will be a diverse 
hub for resources and collaborators that will 
accelerate advances in stem cell-based therapies 
while stimulating Detroit’s economy through its 
role as a stem cell-specific business incubator. Some 
businesses have developed their own technology for 
things such as bone repair therapy. Many others are 
biobanks that facilitate faster research by supplying 
stem cells lines or nutrients required for keeping 
stem cells alive and healthy. 
MitoStem recently received a $200,000 Small 
Business Innovation Research Phase I grant from 
the National Institute of General Medical Sciences 
of the National Institutes of Health to optimize its 
revolutionary stem cell technology developed at 
Wayne State University. Issued under the American 
Recovery and Reinvestment Act of 2009, the grant 
will allow researchers to develop new stem cell lines 
relevant for a variety of diseases, and enable the 
creation of stem cells from patient’s own cells for 
replacement of diseased and damaged tissues. 
“Growing stem cells is not a trivial thing; it’s 
tricky,” Eliason said. “One of the great things about 
this center is that it will build up the expertise in 
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producing and maintaining good stem cell lines. It 
will take a lot of the tedious aspects off scientists’ 
hands and give them more time to do interesting 
research. At the same time, it will allow bio 
companies to make a name for themselves in this 
area of growing demand, boosting the economy of 
Detroit in the process.”
With the multidisciplinary group and 
commercialization center up and running, Brenner 
sees the coming years being prosperous both in 
terms of business growth and in crossing the 
threshold from basic stem cell research to clinical 
applications that will change people’s lives.
 “We’re really getting all the necessary players 
in one place to advance basic research and bring it 
to the next phase as quickly as possible,” Brenner 
said. “It will be incredibly exciting to see where the 
innovation takes us.”
P
A
G
E
 5
6
✼
About Dr. Carol Brenner:         
Dr. Brenner received a B.Sc. in genetics from 
Queen Mary College at the University of London, a 
Ph.D. in molecular embryology from Tufts University 
in Medford, Mass, and was a post-doctorate in 
molecular embryology at the University of California, 
San Francisco. She joined Wayne State in 2007.
Multidisciplinary stem cell team at 
Wayne State University
Wayne State’s unique group of mitochondrial, 
embryonic and basic stem cell biology experts are 
working to model neurodegenerative diseases with 
adult pluripotent stem cells and develop a new 
method for inducing pluripotency that could finally 
make stem cells safe for therapeutics. Here is a 
breakdown of their areas of focus:
Co-principal investigators:
Carol Brenner, Ph.D., associate professor of 
physiology, School of Medicine 
http://www.med.wayne.edu/Embryo/Carol%20
Brenner.html 
James Eliason Ph.D., associate professor of 
internal medicine, School of Medicine and executive 
director of MitoStem  http://techtownwsu.org/
n
Developing “protein transduction,” a potential 
alternative method of inducing pluripotency in adult 
stem cells, that does not require lentiviruses.
Jianjun Wang, Ph.D., associate professor of 
biochemistry, School of Medicine
http://www.med.wayne.edu/biochem/BMB_Faculty/
Wang.html
n
Testing different culture conditions that could 
eliminate stress in reprogrammed stem cells.
Randall Armant, Ph.D., professor of obstetrics 
and gynecology, School of Medicine 
http://www.med.wayne.edu/Anatomy/department/
armant.htm
Dan Rappolee, Ph.D., associate professor of 
obstetrics and gynecology, School of Medicine
http://www.med.wayne.edu/anatomy/department/
Dan.html
n
Creating human stem cell models for neurological 
diseases.
Gyula Acsadi, M.D.,Ph.D., associate professor 
of pediatrics, School of Medicine 
http://neurology.med.wayne.edu/department/
profile.php?id=1838
Graham Parker, Ph.D., assistant professor of 
pediatrics, School of Medicine
http://www.med.wayne.edu/crcm/laboratories/
parker.asp
Michael Shy, Ph.D., professor of neurology, 
School of Medicine
http://www.genetics.wayne.edu/faculty/ 
shy/index.php
n
Studying stem cells in relation to tissue repair and 
regeneration strategies, and in vitro tissue models. 
Howard Matthews, Ph.D., professor of 
chemical engineering and materials science, College 
of Engineering 
http://www.eng.wayne.edu/che/matthew.htm
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